๐ฐ Dirk Arnold News
Page 2 - Dirk Arnold News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dirk Arnold. Real-time updates on events, politics, business and more.
November 7, 2022
70% objective response rate (ORR; n=10) is nearly triple the average ORR of ~25% reported in historical control trials1-4 Data suggest pelareorep synergizes...
June 28, 2022
FinancialNewsMedia.com News Commentary PALM BEACH, Fla., June 28, 2022 /PRNewswire/ -- Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic
June 28, 2022
/PRNewswire/ -- Oncolytics Biotechยฎ Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the pancreatic cancer cohort of the multi-indication phase 1/2 GOBLET...
June 28, 2022
/PRNewswire/ -- Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent treatment. Factors...
June 28, 2022
Partial responses achieved in all patients in cohort's 1b portion Expansion criteria for pancreatic cancer cohort has been met to allow for additional patient enrollment Data suggest
June 28, 2022
/PRNewswire/ -- Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent treatment. Factors...
January 20, 2022
- FinancialNewsMedia.com News Commentary - PALM BEACH, Fla., Jan. 20, 2022 /PRNewswire/ -- Despite significant progress in the treatment of gastric cancer, it is still among the leading
January 20, 2022
/PRNewswire/ -- Oncolytics Biotechยฎ Inc. (NASDAQ: ONCY) (TSX: ONC) provided an enrollment update on the phase 1/2 GOBLET study in a poster presentation at the...
January 20, 2022
/PRNewswire/ -- Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to cancer, across the world....
January 20, 2022
Successfully enrolled first-line metastatic pancreatic and third-line metastatic colorectal safety run-ins Company moving to full enrollment pending independent safety review Multi-center